CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Madrigal Pharmaceuticals, Inc. (Extended hours) - MDGL CFD

296.95
9.45%
Market Trading Hours* (UTC) Opens on Tuesday at 09:00

Tue: 09:00 - 00:00

Wed - Thu: 00:00 - 01:00 09:00 - 00:00

Fri: 00:00 - 01:00 09:00 - 22:00

  • Summary
  • Historical Data
Trading сonditions
Spread 3.10
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023346 %
Charges from full value of position ($-0.23)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001124 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001124%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 271.31
Open 272.74
1-Year Change 11.73%
Day's Range 270.47 - 298.34
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 16, 2025 271.31 -1.73 -0.63% 273.04 275.95 266.47
Jan 15, 2025 271.95 -1.54 -0.56% 273.49 280.95 268.05
Jan 14, 2025 273.49 -31.46 -10.32% 304.95 306.95 273.49
Jan 13, 2025 304.95 -37.00 -10.82% 341.95 342.76 281.95
Jan 10, 2025 336.85 4.90 1.48% 331.95 343.17 320.52
Jan 8, 2025 333.95 20.25 6.46% 313.70 336.07 313.70
Jan 7, 2025 321.92 -0.51 -0.16% 322.43 324.41 314.97
Jan 6, 2025 321.06 10.11 3.25% 310.95 323.04 310.95
Jan 3, 2025 311.95 1.30 0.42% 310.65 321.90 308.96
Jan 2, 2025 310.65 -1.28 -0.41% 311.93 319.84 306.46
Dec 31, 2024 310.94 8.74 2.89% 302.20 316.15 302.20
Dec 30, 2024 314.31 -0.62 -0.20% 314.93 314.93 305.95
Dec 27, 2024 312.23 2.29 0.74% 309.94 317.48 307.83
Dec 26, 2024 312.18 -7.76 -2.43% 319.94 319.94 307.83
Dec 24, 2024 310.96 0.02 0.01% 310.94 313.35 304.90
Dec 23, 2024 308.78 -2.57 -0.83% 311.35 311.35 301.46
Dec 20, 2024 307.02 16.58 5.71% 290.44 311.71 285.29
Dec 19, 2024 289.95 -5.98 -2.02% 295.93 299.90 289.95
Dec 18, 2024 291.44 -17.59 -5.69% 309.03 311.44 289.45
Dec 17, 2024 309.77 2.73 0.89% 307.04 314.65 303.95

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Madrigal Pharmaceuticals, Inc. Company profile

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Madrigal Pharmaceuticals Inc revenues was not reported. Net loss increased 20% to $241.8M. Higher net loss reflects R & D increase of 11% to $194.5M (expense), G & A increase from $10M to $21.1M (expense), Stock-based Compensation in SGA increase of 36% to $16.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$13.09 to -$14.63.

Equity composition

Common Stock $.0001 Par, 10/10, 100M auth., 42,166,779 issd. Insiders control approx. 37.8%. IPO: 2/06/07, 5M shares @ $10 per share by Bear, Stearns & Co. Inc.

Industry: Bio Therapeutic Drugs

200 Barr Harbor Dr Ste 400
WEST CONSHOHOCKEN
PENNSYLVANIA 19428-2978
US

People also watch

ETH/USD

3,482.72 Price
+4.820% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,703.08 Price
-0.430% 1D Chg, %
Long position overnight fee 0.0056%
Short position overnight fee -0.0138%
Overnight fee time 22:00 (UTC)
Spread 0.60

XRP/USD

3.24 Price
-2.090% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01618

US100

21,441.70 Price
+1.820% 1D Chg, %
Long position overnight fee -0.0233%
Short position overnight fee 0.0011%
Overnight fee time 22:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading